Project Grant R01AI190359

Award Date 6/13/25
Completion Date 5/31/30
Dollars Obligated $1.4M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 2-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) worth $162,000 to The Johns Hopkins University to study how atypical B cells can be used to enhance vaccine responses in immunosuppressed individuals. The research project aims to define populations of immunosuppressed individuals who utilize these atypical CD11c+ B cells, assess their interaction with T cells, and target fatty acid oxidation...
This $705,557 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will fund research at Emory University to investigate the role of monocytes and T cells in promoting viral control and clearance of SARS-CoV-2 in the upper and lower respiratory tract. Specifically, the research aims to determine the contribution of monocytes in supporting protective T cell responses,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
This federal Project Grant award of $841,520 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to study microbial biomarkers that can predict multi-drug resistant organism (MDRO) colonization and infection in solid organ transplant recipients. The research leverages the awardee's existing cohort and biobank of over 2,200 samples from liver transplant patients to perform whole-genome sequencing of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $640,735.00 to Emory University to conduct research on understanding the mechanisms of CD8+ tissue-resident memory T cells (TRM) that mediate protection against respiratory virus transmission. The research aims to investigate the characteristics, durability, and molecular mechanisms of respiratory tract TRM...
This Project Grant award for $327,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better understand the role of the CD43 receptor on effector CD8+ T cells during acute allograft rejection. The key objectives are to: Define the effector mechanisms that distinguish CD43+ effector T cells from CD43- effector T cells, including their differentiation pathways, trafficking...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $744,977.00 to Emory University to explore the role of T cells in protecting against respiratory virus transmission. The research aims to define the cellular interactions and molecular mechanisms that allow tissue-resident memory T cells (TRM) to limit the propagation of respiratory viruses like Sendai virus...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $456,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Texas Medical Branch at Galveston (UTMB) to investigate how regulatory mechanisms shape the interleukin-6 (IL-6) immune response during respiratory viral infections. The two-year grant (July 2024 - June 2026) aims to understand how changes in a cis-regulatory element control IL-6 expression in mucosal epithelial cells,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $1,934,958.00 to The University of Texas Southwestern Medical Center to conduct research on the mechanisms by which respiratory viruses, including SARS-CoV-2 and RSV, use cilia on nasal epithelial cells to gain entry into the respiratory system. The research aims to gain a better understanding of the critical...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $196,344 to Emory University to conduct research on identifying immune biomarkers that can predict outcomes in solid organ transplant patients with bloodstream infections. The key objectives are to: 1) identify cytokine, chemokine, and biomarkers associated with septic shock and 30-day mortality in these...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,442,898 to study the effects of vaccination on acute and post-acute respiratory viral infection outcomes in solid organ transplant recipients. The 5-year project, awarded to The Johns Hopkins University, aims to investigate the risks posed by respiratory viral infections, including SARS-CoV-2, RSV, and influenza, to this vulnerable population living with chronic comorbidities, frailty, and heavy immunosuppression. The research will focus on understanding severe clinical manifestations of respiratory viral infections and potential post-acute syndromes, such as organ dysfunction and protracted infections associated with immune evasive mutations, in solid organ transplant recipients. This work is intended to advance scientific knowledge and inform strategies to improve health outcomes for this high-risk patient group.

Generated 7/1/25, 3:21 AM